EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain

Introduction 10–16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of oncology pharmacy practice Vol. 29; no. 4; pp. 854 - 860
Main Authors:	Delgado Sillero, Irene, Lopetegui Lia, Nerea, Sánchez Cousido, Luis Felipe, Rojas Piedra, Mariam, Távara Silva, Blanca, Garrido Onecha, Maria Luisa, Medina Valdivieso, Soledad, Alonso Horcajo, Nieves, Díez Tascón, Cristina, López González, Ana, Castañón López, Carmen, Pedraza Lorenzo, Manuela, García Palomo, Andrés, Martín, Vicente, Diz Tain, Pilar
Format:	Journal Article
Language:	English
Published:	London, England SAGE Publications 01-06-2023 Sage Publications Ltd
Subjects:	Asthenia Chemotherapy Clinical trials Conjunctivitis Diarrhea Epidermal growth factor receptors Gefitinib Lung cancer Metastases Non-small cell lung carcinoma Patients Protein-tyrosine kinase Regression analysis Risk factors Small cell lung carcinoma Survival analysis Spain EGFR mutation TKI NSCLC 19 deletion
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Introduction 10–16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those treated with platinum-based chemotherapy (CT) doublets. Our aim is to perform a real-world survival analysis of patients treated with TKI as first-line therapy at the Hospital of Leon (CAULE) in Spain. The impact on global survival rates and responses to clinical and histopathological factors were also analyzed. Material and methods We retrospectively reviewed patients diagnosed with EGFR-mutated NSCLC who received treatment with EGFR-TKI in the Department of Oncology at the University of Leon Health Center complex between March 2011 and June 2018. Data was analyzed with Kaplan-Meier and Cox regression models to show overall survival (OS), progression-free survival (PFS), and the associated variables. Results 53 patients were included in the study, 50% (n = 27) were treated with gefitinib, 32% (n = 18) with erlotinib and 10% (n = 6) with afatinib. The median OS and PFS were 27.7 months (95% CI: 21–33.8 months) and 18 months (95% CI 14.25–21.89 months), respectively. The variables associated with OS and with PFS were exon19 deletion as a protective factor and presence of extrathoracic metastasis as a risk factor. The most frequent adverse effects were rash, diarrhea, asthenia, and conjunctivitis. Conclusions Real-world analysis of this data confirms that treatment with TKI is beneficial for patients diagnosed with EGFR-mutated NSCLC. Our OS outcomes were similar to those reported in clinical trials.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1078-1552 1477-092X
DOI:	10.1177/10781552221085253